Sterile Aseptic Filling Line Validation

Validation lifecycle support, engineering document remediation, and qualification execution for a monoclonal antibody aseptic filling line from FAT through commissioning and IQ/OQ/PQ.

Executive Summary

A leading biotechnology company engaged Mangan Biopharm to provide validation support for the commissioning, qualification, and documentation lifecycle of a newly installed sterile aseptic filling line designed for monoclonal antibody drug product manufacturing. The project involved a multi-discipline team of internal engineers, validation contractors, and full-time client validation staff, with equipment supplied by multiple vendors and commissioning performed by the client’s engineering organization.

Mangan Biopharm’s scope covered validation lifecycle documentation, Factory Acceptance Testing (FAT) and Site Acceptance Testing (SAT) support, commissioning oversight, Installation Qualification (IQ), Operational Qualification (OQ), Performance Qualification (PQ), supporting critical studies, and regulatory compliance documentation. The project is ongoing, with additional scope to improve procedures, systems and documentation to support regulatory inspections for FDA licensure of the commercial sterile manufacturing site.

Client Profile

A leading biotechnology company that invents, develops, and commercializes medicines for patients with serious diseases, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

The drug product manufactured on this filling line consists of monoclonal antibodies produced from cultured mammalian cells. These therapies require strict aseptic processing throughout manufacturing and are subject to FDA licensure requirements for commercial sterile drug product production.

The Challenge

Bringing a new aseptic filling line from installation through qualification and into commercial readiness is a multi-phase program involving equipment vendors, contract engineering groups, internal engineering, manufacturing and validation teams, and regulatory stakeholders. For this project, three conditions defined the core challenge:

Vendor Documentation Quality and Engineering Lifecycle Document Development

When the project began, the team was converting vendor-supplied functional specifications into client engineering documents. The vendor documents were inconsistent in structure and clarity, with descriptions and illustrations that did not translate directly into usable documentation for qualification purposes. In some cases, content was written in European technical English that did not align with the client’s documentation standards or clearly convey intent to the engineering team responsible for executing qualification. Converting these documents requires subject matter review and substantive editing, not just reformatting.

Protocol Quality Across a Mixed-Experience Team

Mangan Biopharm provided technical leadership and hands-on mentorship throughout the project, working alongside the team to strengthen documentation quality while building long-term capability. Through detailed protocol reviews, coaching, and collaborative problem solving, Mangan Biopharm helped establish a more consistent approach to qualification documentation and reinforced the regulatory expectations associated with computerized systems validation and equipment qualification.

The project team included a significant proportion of engineers earlier in their careers. Gaps in familiarity with protocol structure, proper error correction procedures during execution, and the documentation standards expected of a regulated sterile drug product program created conditions where quality issues could accumulate across a large volume of qualification documentation without being identified at the point of creation.

One example illustrates the compliance risk: audit trail verification was recorded as not applicable in the traceability matrix. For a 21 CFR Part 11-covered system in a sterile drug product environment, audit trail integrity is a core requirement, not an optional test. Identifying and correcting this during the active qualification program required a formal addendum to the traceability matrix — rework that could have been avoided with technical oversight earlier in the documentation review cycle.

Leveraging Commissioning to Streamline Qualification

The high level of automation and system complexity made a traditional qualification strategy, executing complete commissioning followed by separate, full IQ and OQ testing, both inefficient and impractical. To optimize the validation effort while maintaining regulatory compliance, the project adopted a leveraging strategy, where appropriately executed commissioning testing was used to satisfy portions of the qualification requirements.

Successfully implementing this approach requires more than simply reusing commissioning documentation. Mangan Biopharm worked closely with the commissioning team throughout execution to establish clear expectations for test rigor, documentation quality, and traceability necessary for qualification acceptance. By providing ongoing technical oversight, reviewing test execution in real time, and mentoring the commissioning team on qualification-quality documentation practices, Mangan Biopharm helped ensure that commissioning activities generated objective evidence suitable for regulatory leverage.

This collaborative approach minimized duplicate testing while maintaining the integrity of the qualification program. Early engagement during commissioning reduced downstream rework, strengthened documentation quality, and enabled efficient progression into IQ and OQ without compromising compliance or product quality.

The Solution

Mangan Biopharm’s approach focused on these points where documentation quality, technical judgment, and protocol structure carried the most at risk, working across the project team rather than within a single defined deliverable lane.

Engineering Lifecycle Document Standardization

Mangan Biopharm reviewed vendor-supplied functional specifications and converted them into client engineering documents that were structurally sound, clearly written, and usable as the basis for qualification activities. This included reorganizing content, clarifying technical descriptions and illustrations, and revising language where vendor documentation did not meet the client’s documentation standards, without altering technical content.

Acceptance Testing and Qualification Execution

Mangan Biopharm supported FAT at the vendor facility and SAT following installation. Findings and deviations were documented consistently across both activities, with conditions identified during acceptance testing resolved before commissioning and qualification proceeded. Following SAT, Mangan Biopharm executed IQ, OQ, and PQ across all line equipment, with PQ runs conducted across different days, shifts, and operators to demonstrate process repeatability and reproducibility. Supporting qualification studies were performed in parallel: smoke studies within the isolator to confirm laminar airflow and thermal buoyancy effects, Environmental Monitoring Performance Qualification using vaporized hydrogen peroxide with biological indicators at worst-case locations, and an Aseptic Process Simulation under worst-case conditions to demonstrate sterility. Glove testers were qualified for isolator integrity verification and an incubator for e-beam dosimeter conditioning.

Qualification Protocol Development and Technical Oversight

Mangan Biopharm supported the development of qualification protocols across the program, with primary responsibility for authoring the Integrated Operational Qualification (OQ) protocols. As the Integrated OQ served as a structured precursor to Performance Qualification (PQ), these protocols required a comprehensive technical framework that clearly linked process functionality to validation objectives. Mangan Biopharm developed the core technical content, including detailed process descriptions, the scientific and engineering rationale for each test, and clear definitions of the acceptance criteria and intended demonstration of control. This provided the validation team with the technical context and execution framework necessary to perform protocol testing consistently and correctly.

Throughout protocol execution, Mangan Biopharm also provided ongoing technical support to the validation team, including guidance on compliant documentation and error correction practices, interpretation of test results, and application of appropriate statistical methods and data analysis to ensure qualification activities met both regulatory expectations and sound engineering principles.

Documentation Quality and Compliance Interventions

To demonstrate how the system was qualified, Mangan Biopharm maintained the full validation lifecycle documentation set, including URS, DQ, alarm criticality assessments, component criticality assessments, a risk-based traceability matrix, 21 CFR Part 11 assessments, and data integrity risk assessments covering electronic records, data flow, system access, and data security.

Two specific interventions resolved documentation problems with direct compliance implications. First, the audit trail gap in the traceability matrix was resolved through a formal addendum, ensuring audit trail integrity was verified for all 21 CFR Part 11-covered systems on the line. Second, the component criticality assessment template was found to have structural issues that prevented consistent use across the program.

Mangan Biopharm rewrote the template and the revised version was adopted for use across all covered systems.

Commissioning Quality Oversight and Leveraging Support

Mangan Biopharm provided active oversight during commissioning execution to ensure testing was performed completely and documented to the standard required for leveraging into IQ and OQ. This included reviewing test records as they were produced, identifying documentation gaps before they became qualification deficiencies, and providing guidance to the commissioning team on the documentation expectations that distinguish leverageable records from records that would require repeated testing.

Documentation produced under this scope included URS, DQ, alarm criticality assessments, component criticality assessments, a risk-based traceability matrix, 21 CFR Part 11 assessments, and data integrity risk assessments covering electronic records, data flow, system access, and data security.

The Results

The following conditions reflect the project’s state at the time of publication. The project is ongoing, with activities continuing toward FDA licensure for commercial sterile manufacturing.

• Line qualified for process validation: Through FAT, SAT, commissioning, IQ, OQ execution, supported smoke studies, VHP sterilization qualification, and aseptic process simulation, the filling line has been established in a controlled state suitable for process validation.
• Engineering lifecycle documents remediated: Vendor-supplied functional specifications were converted into client engineering documents meeting site documentation standards, providing a clear and accurate basis for protocol development and qualification execution.
• Audit trail compliance gap formally resolved: An audit trail verification gap in the traceability matrix was identified and resolved through a formal addendum. Audit trail integrity has been verified for all 21 CFR Part 11-covered systems on the line.
• Component criticality assessment template revised and adopted: A revised template was developed to address structural issues and adopted across the program, improving documentation consistency for all covered systems.
• Commissioning test data quality sufficient for leveraging: Active oversight during commissioning ensured records met the documentation standard required for leveraging into IQ and OQ, avoiding repeated testing and associated schedule impact.
• Qualification program quality maintained across a mixed-experience team: Technical guidance on protocol structure, error correction procedures, statistical methods, and data analysis was provided throughout the program, ensuring documentation quality met the standard required for a sterile drug product validation program.
• Alarm criticality assessment in progress: Work is ongoing on the alarm criticality assessment for the new EMS system, where all alarms are new and require assessment against criticality criteria.

Project Scope

The filling line equipment covered under this validation program:

Key Takeaways

This project illustrates conditions common to new sterile filling line validation programs, particularly those involving multi-vendor equipment, highly automated systems, and mixed-experience project teams. The following observations apply broadly to engineering and validation professionals managing similar programs:

For automation lifecycle upgrade projects, see our CompactLogix migration case study. For process safety system implementation, see our UPSS SIL 2 case study.